University of Cincinnati Cancer Institute Joins Caris Life Sciences’ Precision Oncology Alliance

Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that the University of Cincinnati Cancer Institute (UCCI) has joined Caris’ Precision Oncology Alliance™ (POA). UCCI marks the 20th institution to join the growing alliance, which was established to develop standards of care and best practices for tumor profiling by leveraging the Caris experience dataset of more than 125,000 clinical cases with thousands of associated patient outcomes.

“The University of Cincinnati Cancer Institute has been a longstanding cancer treatment leader that brings a multi-disciplinary approach to treat patients with complex and advanced diseases in the greater Cincinnati metropolitan area,” said W. Michael Korn, M.D., Chief Medical Officer of Caris Life Sciences. “Their commitment to cutting edge research and new approaches to personalized diagnostics and treatment make them an excellent member for the alliance and we look forward to working closely with them to contribute and explore the Caris experience dataset to advance the utility of tumor profiling in oncology.”

The POA, which now consists of 20 academic, hospital and community-based cancer institutions, including five NCI-Designated Cancer Centers, is broadening patient access to precision medicine tools and establishing evidence-based standards for tumor profiling and molecular testing in oncology. The health system will leverage Caris’ comprehensive genomic profiling plus (CGP+) tumor profiling service, Caris Molecular Intelligence®, to enable the practice of precision medicine by identifying therapy options and clinical trial opportunities based on the unique molecular characteristics of a patient’s tumor. UCCI will also actively participate in collecting molecular data and longitudinally tracking outcomes data for those patients that have had their tumors profiled.

“Cancer care is rapidly evolving toward treatment management based on the molecular profile of the tumor rather than its tissue of origin,” said Thomas Herzog, M.D., Deputy Director for UCCI and Professor in the Department of Obstetrics and Gynecology at UC College of Medicine. “This is exemplified by the approval of pembrolizumab for microsatellite-high expressing tumors, PARP inhibitors for BRCA mutations and the development of larotrectinib for treating tumors that express TRK fusion. Given this pivot, we anticipate tumor profiling to become the standard of care diagnostic approach for all patients with malignancies. We look forward to contributing to the development of this important platform to optimize cancer treatment and improve outcomes for our patients.”

Since 2008, Caris Molecular Intelligence has been assessing DNA, RNA and proteins to reveal a molecular profile to guide more precise and individualized treatment decisions. By analyzing the unique molecular characteristics of an individual patient’s cancer, our results help inform treatment decisions by identifying therapies that have the potential to be most effective and to rule out those that are less likely to work.